Daniel J O Roche1, Matthew J Worley2, Kelly E Courtney2, Spencer Bujarski1, Edythe D London3,4, Steven Shoptaw5, Lara A Ray6,7. 1. Department of Psychology, University of California, Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA. 2. Department of Psychiatry, University of California, San Diego, San Diego, CA, USA. 3. Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA. 4. Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA. 5. Department of Family Medicine, University of California, Los Angeles, Los Angeles, CA, USA. 6. Department of Psychology, University of California, Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA. lararay@psych.ucla.edu. 7. Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA. lararay@psych.ucla.edu.
Abstract
RATIONALE: Reductions in cue-induced craving and subjective response to drugs of abuse are commonly used as initial outcome measures when testing novel medications for the treatment of addiction. Yet neither the relationship between these two measures at the individual level nor the moderating effects of pharmacotherapies on this relationship has been examined. OBJECTIVE: This secondary data analysis sought to examine (1) the predictive relationship between cue-induced craving and subsequent acute subjective response to methamphetamine (MA) and (2) whether the opioid-receptor antagonist naltrexone moderated this association in a sample of non-treatment-seeking individuals who met DSM-IV criteria for MA use disorder (abuse or dependence). METHODS: Participants (n = 30) completed two 4-day medication regimens (oral naltrexone 50 mg or placebo, in a randomized, counterbalanced, and double-blind fashion). On day 4 of each medication regimen, participants completed a cue-reactivity paradigm followed by intravenous MA administration. Methamphetamine craving was assessed after the cue-reactivity paradigm, and subjective response to MA was assessed during MA infusion. RESULTS: Cue-induced craving for MA was positively associated with post-infusion subjective MA effects, including positive (i.e., stimulation, good effects, feel drug, high), negative (i.e., anxious and depressed), and craving-related (i.e., want more, would like access to drug, crave) responses. Naltrexone, vs. placebo, significantly reduced the association between cue-induced craving and positive subjective response to MA. CONCLUSIONS: The findings indicate that naltrexone moderates the predictive relationship between cue-induced craving and positive subjective effects of MA, thereby suggesting a behavioral mechanism by which naltrexone may be efficacious in treating MA use disorder.
RATIONALE: Reductions in cue-induced craving and subjective response to drugs of abuse are commonly used as initial outcome measures when testing novel medications for the treatment of addiction. Yet neither the relationship between these two measures at the individual level nor the moderating effects of pharmacotherapies on this relationship has been examined. OBJECTIVE: This secondary data analysis sought to examine (1) the predictive relationship between cue-induced craving and subsequent acute subjective response to methamphetamine (MA) and (2) whether the opioid-receptor antagonist naltrexone moderated this association in a sample of non-treatment-seeking individuals who met DSM-IV criteria for MA use disorder (abuse or dependence). METHODS: Participants (n = 30) completed two 4-day medication regimens (oral naltrexone 50 mg or placebo, in a randomized, counterbalanced, and double-blind fashion). On day 4 of each medication regimen, participants completed a cue-reactivity paradigm followed by intravenous MA administration. Methamphetamine craving was assessed after the cue-reactivity paradigm, and subjective response to MA was assessed during MA infusion. RESULTS: Cue-induced craving for MA was positively associated with post-infusion subjective MA effects, including positive (i.e., stimulation, good effects, feel drug, high), negative (i.e., anxious and depressed), and craving-related (i.e., want more, would like access to drug, crave) responses. Naltrexone, vs. placebo, significantly reduced the association between cue-induced craving and positive subjective response to MA. CONCLUSIONS: The findings indicate that naltrexone moderates the predictive relationship between cue-induced craving and positive subjective effects of MA, thereby suggesting a behavioral mechanism by which naltrexone may be efficacious in treating MA use disorder.
Authors: Dean F Wong; Hiroto Kuwabara; David J Schretlen; Katherine R Bonson; Yun Zhou; Ayon Nandi; James R Brasić; Alane S Kimes; Marika A Maris; Anil Kumar; Carlo Contoreggi; Jonathan Links; Monique Ernst; Olivier Rousset; Stephen Zukin; Anthony A Grace; Jae Sung Lee; Charles Rohde; Donald R Jasinski; Albert Gjedde; Edythe D London Journal: Neuropsychopharmacology Date: 2006-09-13 Impact factor: 7.853
Authors: Nora D Volkow; Gene-Jack Wang; Frank Telang; Joanna S Fowler; Jean Logan; Anna-Rose Childress; Millard Jayne; Yeming Ma; Christopher Wong Journal: J Neurosci Date: 2006-06-14 Impact factor: 6.167
Authors: Milky Kohno; Laura E Dennis; Holly McCready; Daniel L Schwartz; William F Hoffman; P Todd Korthuis Journal: Drug Alcohol Depend Date: 2018-09-21 Impact factor: 4.492
Authors: Madhukar H Trivedi; Robrina Walker; Walter Ling; Adriane Dela Cruz; Gaurav Sharma; Thomas Carmody; Udi E Ghitza; Aimee Wahle; Mora Kim; Kathy Shores-Wilson; Steven Sparenborg; Phillip Coffin; Joy Schmitz; Katharina Wiest; Gavin Bart; Susan C Sonne; Sidarth Wakhlu; A John Rush; Edward V Nunes; Steven Shoptaw Journal: N Engl J Med Date: 2021-01-14 Impact factor: 91.245
Authors: Milky Kohno; Angelica M Morales; Laura E Dennis; Holly McCready; William F Hoffman; P Todd Korthuis Journal: Front Psychiatry Date: 2019-09-03 Impact factor: 4.157
Authors: Lee Seng Esmond Seow; Wei Jie Ong; Aditi Hombali; P V AshaRani; Mythily Subramaniam Journal: Int J Environ Res Public Health Date: 2020-09-07 Impact factor: 3.390